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ALT-801, a fusion of interleukin-2 and a single-chain
T cell receptor domain specific to a p53 peptide/HLA-
A*0201 complex, has shown immune cell-mediated activ-
ity in human xenograft tumor SCID mouse models and in
patients with metastatic malignancies. To further investi-
gate the antitumor efficacy of this fusion protein in immu-
nocompetent mice, we conducted mechanism-of-action
studies in an orthotopic murine muscle invasive bladder
cancer model. ALT-801 treatment (1.6 mg/kg i.v., day 7,
10, 14, 17 post-tumor instillation) significantly prolonged
survival of C57BL/6 mice bearing orthotopic MB49luc
bladder tumors when compared to equivalent treatment
with either IL-2 (0.4 mg/kg) or PBS (8 mice/group; median
survival: ALT-801, 48.5 days vs. IL-12, 36 days; vs.PBS,
33.5 days, p < 0.001), consistent with previous findings in
xenograft tumor models. Tumor-bearing mice that were
cured by ALT-801 treatment were also protected from
subsequent MB49luc tumor re-challenge 2-3 months later
indicating induction of memory immune responses.
Studies in this model using immune cell depletion and KO
mice revealed that ALT-801-mediated antitumor activity
was dependent on CD4+ and CD8+ T cells and macro-
phage but not NK cells and required expression of IFN-g
(based on survival endpoint: PBS vs. ALT-801 or ALT-801
+anti-NK1.1 Ab depletion, p < 0.05; PBS vs. ALT-801
+CD8 Ab, CD4 Ab or clophosome depletion, P > 0.05;
PBS vs. ALT-801 treatment of tumor-bearing IFN-g or
IFN-gR KO mice, P > 0.05). Consistent with these results,
IHC, adoptive cell transfer and expression array studies
showed that ALT-801 treatment led to activation and
proliferation of CD4+ and CD8+ T cells which migrate
from the lymphoid tissues to the tumor site where they
secrete IFN-g. Twenty hours after ALT-801 administra-
tion, tumor associated-macrophages (TAM) in the bladder
of tumor-bearing mice were also transiently repolarized
from an M2 (tumor promoting) to an M1 (tumor killing)
phenotype in an IFN-g dependent manner. Additionally, in
vivo ALT-801 treatment induced innate-like CD8
+CD44high memory T cells to proliferate and upregulate
NKG2D receptors. These cells may contribute to elevated
splenocyte cytotoxic activity against mouse and human
bladder tumor cells that was seen after ALT-801 adminis-
tration. The results of these studies suggest that ALT-801
induces IFN-g-dependent TAM repolarization and non-
specific CD8+ memory effector T cells that promote
robust and rapid antitumor activity in mice bearing ortho-
topic MB49luc bladder tumors. This novel immunostimu-
latory mechanism-of-action appears to be distinct from
that of IL-2 or other T cell-based immunotherapeutics
and is currently being assessed in bladder cancer patients
under treatment with ALT-801.
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